Trial Identifier: | D4326C00003 |
Sponsor: | AstraZeneca |
NCTID:: | NCT05516498 |
Start Date: | October 2022 |
Primary Completion Date: | November 2024 |
Study Completion Date: | November 2024 |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
No documents have been posted yet.
Country | Location |
---|---|
AT | Wien, AT, 1090 |
BE | Edegem, BE, 2650 |
CH | Bern, CH, 3010 |
CH | Lugano, CH, 6900 |
DE | Dresden, DE, 01307 |
DE | Jena, DE, 07747 |
DE | Magdeburg, DE |
DE | Mainz, DE, 55131 |
DK | Hvidovre, DK, 2650 |
ES | Barcelona, ES, 08036 |
ES | Barcelona, ES, 08041 |
ES | Madrid, ES, 28034 |
ES | Santander, ES, 39008 |
ES | Sevilla, ES, 41013 |
ES | Zaragoza, ES, 50009 |
NL | Amsterdam, NL, 1105 AZ |
US, AL | Birmingham, AL, US, 35233 |
US, CA | Pasadena, CA, US, 91105 |
US, CA | San Diego, CA, US, 92103 |
US, CA | San Francisco, CA, US, 94115 |
US, CA | West Hollywood, CA, US, 90048 |
US, LA | New Orleans, LA, US, 70115 |
US, MN | Rochester, MN, US, 55905 |
US, NY | New York, NY, US, 10016 |
US, SC | Charleston, SC, US, 29425 |
US, VA | Charlottesville, VA, US, 22903 |
US, VA | Richmond, VA, US, 23298 |
US, WI | Milwaukee, WI, US, 53226 |